{"entity":{"id":"nct06724263","kind":"trial","name":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Tasly Biopharmaceuticals Co., Ltd., not yet recruiting.","summary":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors is a phase 2, interventional study registered as NCT06724263 by Tasly Biopharmaceuticals Co., Ltd., with a registry enrolment figure of 120 participants, started 2024-12 and due to reach its primary completion in 2026-08. Interventions recorded: B1962. Conditions listed: Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervical Cancers; Small Cell Lung Cancer; Hepatocellular Carcinoma (HCC); Colorectal Cancer; Non-Squamous Non-Small Cell Lung Cancer. Triple-negative eligibility wording from the registry: \"* Triple-negative breast cancer: pathologically confirmed unresectable locally advanced or metastatic breast cancer with negative ER, PR, and HER-2\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06724263","url":"https://clinicaltrials.gov/study/NCT06724263"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06724263","phase":"2","setting":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","participation":[{"nct":"NCT06724263","source":"https://clinicaltrials.gov/study/NCT06724263","fetchedAt":"2026-10-07T16:54:58.037Z","studySha256":"bfbdaaff011da571490eb38e97b1eb8d95891a0494ec671c5c5c5c134643618a","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2024-12-09","leadSponsor":"Tasly Biopharmaceuticals Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":120,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-12","startedType":"estimated","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06724263/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}